Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 572 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 Cervical screening in Wales extended to every 5 years: Why the... January 7, 2022 Cancer in My Community: Providing Free Access to Cancer Care in... September 17, 2020 FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer July 8, 2020 Load more HOT NEWS Prostate Cancer Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... Prize winning early detection research Opinion: ‘We need to increase testing in primary care’
